New drug discovery strategies for rheumatoid arthritis: A niche for nonhuman primate models to address systemic complications in inflammatory arthritis

Expert Opinion on Drug Discovery

Volumn 7, Issue 4, 2012, Pages 315-325

  Vierboom, Michel ^a   Breedveld, Elia ^a   'T Hart, Bert A ^a,b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

anemia; animal models; biologicals; cardiovascular disease; collagen induced arthritis; dyslipidemia; nonhuman primate

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CHOLESTEROL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOCOSAHEXAENOIC ACID; ETANERCEPT; GOLIMUMAB; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; INFLIXIMAB; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TRIACYLGLYCEROL;

ANEMIA; ARTHRITIS; ATHEROGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BACTERIAL INFECTION; BLOOD CHEMISTRY; CARDIOVASCULAR DISEASE; COLLAGEN INDUCED ARTHRITIS; COMORBIDITY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EARLY DIAGNOSIS; ERYTHROPOIESIS; EXPERIMENTAL MODEL; HEMATOCRIT; HUMAN; NEOPLASM; NONHUMAN; PATIENT MONITORING; PRIMATE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHESUS MONKEY; RHEUMATOID ARTHRITIS;

ANEMIA; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CALLITHRIX; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; DYSLIPIDEMIAS; HUMANS; MACACA MULATTA;

EID: 84859315417     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.666523     Document Type: Review

References (92)

1. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4(Suppl 3):S265-72
2. source: the National Rheumatoid Arthritis Foundation. 2012
3. Bax M, van Heemst J, Huizinga TW, et al. Genetics of rheumatoid arthritis: what have we learned? Immunogenetics 2011;63(8):459-66
4. Gregersen PK, Lee HS, Batliwalla F, et al. PTPN22: setting thresholds for autoimmunity. Semin Immunol 2006;18(4):214-23 (Pubitemid 43903284)
5. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50(3):709-15 (Pubitemid 38326168)
6. van der Helm-van Mil AH, Huizinga TW, de Vries RR, et al. Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis Rheum 2007;56(6):1728-35 The article reviews the available data on serology and genetics defining subsets of patients. I believe a first step in personalized medicine for RA. (Pubitemid 47110372)
7. van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 2008;10(2):205
8. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146(6):406-15 This study is a good example of what can be achieved with the 'treat to target' strategy. With intensive and objective monitoring of disease activity and adjustments of therapy, low disease activity is a realistic goal in RA. (Pubitemid 351650575)
9. Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009;60(5):1222-31
10. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61(1):4-12
11. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69(6):964-75
12. Maggon, Krishnan; Guild (KPG), Knol Publishing. Top Ten/Twenty Best Selling Drugs 2010:World Best Selling Human Medicinal Brands 2010, Top Ten, Top Twenty, First Global Market Report [Internet]. Version 70. Knol. 2011 Nov 10. Available from: http://knol.google.com/k/krishan-maggon/top-ten-twentybest- selling-drugs-2010/3fy5eowy8suq3/141.
13. Tang W, Lu Y, Tian QY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011;332(6028):478-8414.
14. Wu H, Siegel RM. Medicine. Progranulin resolves inflammation. Science 2011;332(6028):427-8
15. Liu CJ. Progranulin: a promising therapeutic target for rheumatoid arthritis. FEBS Lett 2011;585(23):3675-80
16. Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39(6):425-41 This study gives a robust overview of response rates to different biological treatments, thereby highlighting the unmet needs in the treatment of RA.
17. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-50
18. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9(2):R28
19. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371(9617):987-97 (Pubitemid 351392039)
20. Nakashima Y, Kondo M, Harada H, et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol 2010;20(4):343-52
21. Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 2006;18(3):277-81 (Pubitemid 43740380)
22. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60(7):1895-905
23. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-23 (Pubitemid 41317434)
24. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349(20):1907-15 (Pubitemid 37409707)
25. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP Antibody, a marker for the early detection of rheumatoid arthritis. Ann NY Acad Sci 2008;1143:268-85
26. van Boekel MA, Vossenaar ER, van den Hoogen FH, et al. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4(2):87-93 (Pubitemid 34257342)
27. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54(9):2793-806 (Pubitemid 44497758)
28. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54(5):1390-400
29. Magnusson M, Brisslert M, Zendjanchi K, et al. Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. Rheumatology (Oxford) 2010;49(10):1911-19
30. Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 2010;10(8):605-11
31. van den Broek M, Huizinga TW, Dijkmans BA, et al. Drug-free remission: is it already possible? Curr Opin Rheumatol 2011;23(3):266-72
32. Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol 2011;7(11):639-52
33. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011;7(7):399-408
34. Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56(11):3583-7 (Pubitemid 350100691)
35. Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 2005;12(3):167-81 (Pubitemid 41375640)
36. Holmdahl R, Bockermann R, Backlund J, et al. The molecular pathogenesis of collagen-induced arthritis in mice--a model for rheumatoid arthritis. Ageing Res Rev 2002;1(1):135-47 (Pubitemid 38344149)
37. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J 1991;10(13):4025-31 (Pubitemid 21905432)
38. Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191(2):313-20 (Pubitemid 30060920)
39. Sakaguchi S, Sakaguchi N. Animal models of arthritis caused by systemic alteration of the immune system. Curr Opin Immunol 2005;17(6):589-94 (Pubitemid 41506902)
40. Matsuno H, Yudoh K, Uzuki M, et al. The SCID-HuRAg mouse as a model for rheumatoid arthritis. Mod Rheumatol 2001;11:6-9 (Pubitemid 32927095)
41. Mestas J, Hughes CC. Of Mice and Not Men: differences between mouse and human immunology. J Immunol 2004;172(5):2731-8 (Pubitemid 38263654)
42. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003;111(12):1887-95 (Pubitemid 38057733)
43. Sachs DH. Tolerance: of mice and men. J Clin Invest 2003;111(12):1819-21 (Pubitemid 38057726)
44. Bakker NP, van Erck MG, Otting N, et al. Resistance to collagen-induced arthritis in a nonhuman primate species maps to the major histocompatibility complex class I region. J Exp Med 1992;175(4):933-7
45. Vierboom MP, Jonker M, Bontrop RE, et al. Modeling human arthritic diseases in nonhuman primates. Arthritis Res Ther 2005;7(4):145-54
46. Vierboom MP, Jonker M, Tak PP, et al. Preclinical models of arthritic disease in non-human primates. Drug Discov Today 2007;12(7-8):327-35
47. Goossens PH, Schouten GJ, 't Hart BA, et al. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys. Hum Gene Ther 1999;10(7):1139-49 (Pubitemid 29231858)
48. Vierboom MP, Zavodny PJ, Chou CC, et al. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum 2005;52(2):627-36 (Pubitemid 40216329)
49. Brok HP, Tekoppele JM, Hakimi J, et al. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin Exp Immunol 2001;124(1):134-41 (Pubitemid 32476943)
50. Bakker NP, Van Besouw N, Groenestein R, et al. The anti-arthritic and immunosuppressive effects of cyclosporin A on collagen-induced arthritis in the rhesus monkey. Clin Exp Immunol 1993;93(3):318-22 (Pubitemid 23276254)
51. Zheng B, Zhang X, Guo L, et al. IgM plays an important role in induction of collagen-induced arthritis. Clin Exp Immunol 2007;149(3):579-85 (Pubitemid 47256157)
52. Vierboom MP, Breedveld E, Kondova I, et al. Collagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritis. Arthritis Res Ther 2010;12(5):R200
53. Vierboom MP, Breedveld E, Kondova I, et al. The significance of non-human primates as preclinical models of human arthritic disease. Expert Opin Drug Discov 2008;3(3):1-11
54. Vierboom MPM, Breedveld E, 't Hart BA. Preclinical evaluation of anti-rheumatic drugs in a non-human primate model of arthritic disease. Drug Discov Today 2008;5(2):89-95
55. Otting N, Heijmans CM, Noort RC, et al. Unparalleled complexity of the MHC class I region in rhesus macaques. Proc Natl Acad Sci USA 2005;102(5):1626-31 (Pubitemid 40209218)
56. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59(12):1690-7
57. Mendis S, Nordet P, Fernandez-Britto JE, et al. Atherosclerosis in children and young adults: an overview of the world health organization and international society and federation of cardiology study on pathobiological determinants of atherosclerosis in youth study (1985-1995). Prev Control 2005;1:3-15 (Pubitemid 44296183)
58. Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med 2002;21(2):213-37 (Pubitemid 34289953)
59. Berenson GS, Srinivasan SR, Hunter SM, et al. Risk factors in early life as predictors of adult heart disease: the Bogalusa Heart Study. Am J Med Sci 1989;298(3):141-51 The three studies described in the [57-59] describe the causal relation between lifestyle, the development of atherosclerosis and the risk of cardiovascular disease.
60. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340(2):115-26
61. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135-43 (Pubitemid 34212626)
62. Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62(9):842-5 (Pubitemid 37026494)
63. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009;38(5):372-81
64. Situnayake RD, Kitas G. Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis 1997;56(6):341-2
65. Ansell BJ, Navab M, Watson KE, et al. Anti-inflammatory properties of HDL. Rev Endocr Metab Disord 2004;5(4):351-8 (Pubitemid 39388752)
66. Kremer JM, Lawrence DA, Petrillo GF, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. Arthritis Rheum 1995;38(8):1107-14
67. Geusens P, Wouters C, Nijs J, et al. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. Arthritis Rheum 1994;37(6):824-9 (Pubitemid 24184532)
68. Iso H, Kobayashi M, Ishihara J, et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006;113(2):195-202
69. Gilroy DW, Lawrence T, Perretti M, et al. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004;3(5):401-16 (Pubitemid 38618123)
70. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 2010;177(4):1576-91
71. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8(5):349-61 (Pubitemid 351595216)
72. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196(8):1025-37 (Pubitemid 35231761)
73. Serhan CN. The resolution of inflammation: the devil in the flask and in the details. Faseb J 2011;25(5):1441-8
74. Albers JJ, Pitman W, Wolfbauer G, et al. Relationship between phospholipid transfer protein activity and HDL level and size among inbred mouse strains. J Lipid Res 1999;40(2):295-301 (Pubitemid 29069804)
75. Ishibashi S, Brown MS, Goldstein JL, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92(2):883-93 (Pubitemid 23262411)
76. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1995;36(11):2320-8
77. Kowala MC, Recce R, Beyer S, et al. Characterization of atherosclerosis in LDL receptor knockout mice: macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis 2000;149(2):323-3078.
78. Nikolaisen C, Figenschau Y, Nossent JC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol 2008;35(3):380-6
79. Han C, Rahman MU, Doyle MK, et al. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol 2007;34(11):2177-82 (Pubitemid 350076876)
80. Vreugdenhil G, Lowenberg B, Van Eijk HG, et al. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest 1992;22(7):488-93
81. Jongen-Lavrencic M, Peeters HR, Backx B, et al. R-h-erythropoietin counteracts the inhibition of in vitro erythropoiesis by tumour necrosis factor alpha in patients with rheumatoid arthritis. Rheumatol Int 1994;14(3):109-13 (Pubitemid 24304616)
82. Peeters HR, Jongen-Lavrencic M, Bakker CH, et al. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 1999;18(5-6):201-6 (Pubitemid 29294983)
83. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101(7):2461-3 (Pubitemid 36857598)
84. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102(3):783-8 (Pubitemid 36917762)
85. Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, et al. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 1996;55(10):739-44 (Pubitemid 26354435)
86. Desai S, Myles M, Kaplan M. Getting to the Heart of the Matter: The Need for More Aggressive Management of Cardiovascular Risk Factors in Rheumatoid Arthritis Abstract. ACR; 2011
87. Yuan XM, Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann Med 2003;35(8):578-91 This review describes the link between dyslipidemia and anemia to the development of atherosclerosis. (Pubitemid 38005315)
88. Kawashiri SY, Kawakami A, Yamasaki S, et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011;31(4):451-6
89. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20(3):222-32
90. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP- 690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63(8):1150-8
91. Masuda J, Ross R. Atherogenesis during low level hypercholesterolemia in the nonhuman primate. I. Fatty streak formation. Arteriosclerosis 1990;10(2):164-77 (Pubitemid 20103578)
92. Masuda J, Ross R. Atherogenesis during low level hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis 1990;10(2):178-87